

**Mineralys Therapeutics, Inc.
150 N. Radnor Chester Road
Suite F200
Radnor, Pennsylvania 19087**

April 9, 2024

VIA EDGAR

U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

**Re: Mineralys Therapeutics, Inc.
Registration Statement on Form S-3, as amended
File No. 333-278122**

Ladies and Gentlemen:

Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Mineralys Therapeutics, Inc., respectfully requests that the effective date of the Registration Statement on Form S-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on April 11, 2024, or as soon as practicable thereafter.

If you have any questions or require additional information, please contact Jonathan R. Zimmerman of Faegre Drinker Biddle & Reath LLP at (612) 766-8419. Thank you for your assistance and cooperation in this matter.

Very truly yours,

MINERALYS THERAPEUTICS, INC.

By: /s/ Adam Levy
Adam Levy
Chief Financial Officer

cc: Jon Congleton, Chief Executive Officer, Mineralys Therapeutics, Inc.
Jonathan R. Zimmerman, Faegre Drinker Biddle & Reath LLP
Griffin D. Foster, Faegre Drinker Biddle & Reath LLP
Ilij Mujalovic, Shearman & Sterling LLP